Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Impact · against what's priced in

Helus Pharma provides a concrete catalyst for Q4 2026 by completing its Phase 3 enrollment ahead of schedule, reducing execution risk for HLP003. The strong sales growth for J&J's Spravato validates the commercial appetite for clinic-administered MDD treatments, benefiting the overall category.

HELP+0.50

No priced-in read yet